Discovery and Development of Semaglutide

Yumeng Duan, Ziyao Wan

2022

Abstract

Diabetes Mellitus is a universal disease around the world. There are many different types of drugs for treatment, among which the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have attached much attention in recent years. Semaglutide, one of the GLP-1 RAs, is a long-acting diabetes drug developed by Novo Nordisk. Compared with traditional diabetes drugs, semaglutide possesses a longer biological half-life, which conduces to reduce the dosing frequency. And based on the general preparation of semaglutide, Novo Nordisk made changes to the dosage form and made it into the oral drug. In 2019, FDA launched the new drug, oral semaglutide. Oral semaglutide has been proved that it still maintains good effectiveness, and oral semaglutide has better safety and can reduce the occurrence of hypoglycemia through pre-clinical and clinical trials. This review introduces the mechanism, structure, pre-clinical and clinical trials of semaglutide and discusses the entire process from the research and development background to the market.

Paper Citation

in Harvard Style

Duan Y. and Wan Z. (2022). Discovery and Development of Semaglutide. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 1119-1130. DOI: 10.5220/0011378500003443

in Bibtex Style

@conference{icbeb22,
author={Yumeng Duan and Ziyao Wan},
title={Discovery and Development of Semaglutide},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={1119-1130},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011378500003443},
isbn={978-989-758-595-1},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - Discovery and Development of Semaglutide
SN - 978-989-758-595-1
AU - Duan Y.
AU - Wan Z.
PY - 2022
SP - 1119
EP - 1130
DO - 10.5220/0011378500003443